Figure 1.

Drug costs (in 2011 euros) and effectiveness evaluated as sustained virologic response. Each symbol represents drug costs versus the proportion of patients who achieve SVR among the competing strategies. (See, CammĂ  C, et al. Hepatology 2012;56:850-860).

Petta and Craxì BMC Infectious Diseases 2012 12(Suppl 2):S3   doi:10.1186/1471-2334-12-S2-S3